| This company develops blood tests designed to catch diseases like cancer and sepsis earlier, and instead of building its own labs, it licenses the technology to larger partners. |
Please See Disclosures Below*
Take a Look At VolitionRX (VNRX)
Volition is building blood tests that look for disease signals in nucleosomes, and licensing the technology to larger partners instead of building its own labs.
Hey Folks,
In medical diagnostics, there is a constant push to find diseases earlier, when they are more treatable. One small company that has been quietly building technology in this space is VolitionRX (NYSE: VNRX). Its approach to blood-based testing has attracted partnerships with some notable names in diagnostics...
Key Points
| Blood tests built on nucleosomes. Volition's Nu.Q platform measures nucleosomes in blood and looks for patterns that can indicate disease, and it is designed to run anywhere from large reference labs to point-of-care devices. | |
| Four product areas. Veterinary cancer screening, human cancer applications, sepsis and inflammatory conditions, and research services for drug developers. | |
| One product already selling. The Nu.Q Vet Cancer Test is available in the U.S., Europe, Australia and parts of Asia through distributors including Antech and IDEXX, with over 120,000 tests and components sold in 2024. | |
| Licenses instead of labs. Volition develops the technology and patents, then licenses them to partners who commercialize. The Antech deal has produced $10 million upfront and $13 million in milestones to date. |
What Volition Does
At its core, Volition develops blood tests based on nucleosomes. The company's technology measures these nucleosomes and looks for specific patterns that can indicate disease, and it has built its Nu.Q platform around that science. Rather than requiring expensive equipment or specialized laboratories, the tests are designed to work across different settings, from large reference labs to point-of-care devices that could be used in a doctor's office.
Four Product Lines
Veterinary testing is the most commercially advanced product. The Nu.Q Vet Cancer Test helps veterinarians screen dogs for cancer through a simple blood draw. Cancer is the leading cause of death in dogs over age two, and early detection can significantly improve outcomes. The test is already sold in the United States, Europe, Australia and parts of Asia through distributors including Antech and IDEXX, and the company sold over 120,000 tests and components in 2024.
Human cancer applications have started moving beyond pure clinical validation. Volition is working with hospitals in Europe and Asia to study early detection, monitoring treatment response, and detecting minimal residual disease, the small number of cancer cells that can remain after treatment and cause relapse. Three French hospitals have completed certification of the Nu.Q Cancer assays, a reimbursement submission is in preparation, and routine clinical sales in France are expected to begin in Q4 2026.
Sepsis and inflammatory conditions are another major focus. Sepsis is one of the leading causes of death in hospitals worldwide, claiming an estimated 21 million lives in 2021, and current diagnostic methods are slow and imprecise. Volition's Nu.Q NETs test measures neutrophil extracellular traps, part of the immune response that is associated with poor outcomes in sepsis patients. The test has received CE marking for use in Europe.
Research services round out the four. Through Nu.Q Discover, pharmaceutical companies and scientists can use Volition's technology in drug development and clinical studies.
A Second Platform: Capture-Seq
Beyond the four Nu.Q pillars, Volition has been developing a separate liquid biopsy platform called Capture-Seq, aimed at early cancer detection and minimal residual disease testing. It works by enriching and purifying plasma samples to isolate circulating tumor DNA for downstream analysis. In March, the company reported over 99% purity in isolating circulating tumor DNA from plasma, and a blinded validation cohort of 81 subjects (colorectal and lung cancer patients alongside healthy controls) achieved over 95% sensitivity for Stage I and Stage II cancers at 95% specificity. The company positions it as a separate pipeline asset from Nu.Q that could compete in spaces currently dominated by much larger liquid biopsy players.
Licensing Rather Than Building
One thing that sets Volition apart from many diagnostics companies is its asset-light approach. Rather than building its own laboratories, manufacturing facilities and sales teams, the company focuses on developing technology and intellectual property, then licenses it to larger partners who handle commercialization.
That strategy has produced some notable partnerships. Antech, a major veterinary diagnostics company, holds an exclusive licensing agreement that has generated $10 million upfront and $13 million in milestone payments to date. Werfen recently signed a research license for the NETs technology focused on antiphospholipid syndrome, and Hologic Diagenode entered a co-marketing agreement for research applications. The company says it is in confidential licensing discussions with multiple large diagnostic and liquid biopsy companies worldwide.
For a licensing model, patent protection is critical. According to its corporate materials, Volition has dozens of patents granted, with coverage extending to 2044.
What To Watch
Management projects that its Nu.Q lung cancer applications, spanning screening, MRD and prognostic uses, could reach over 3 million tests annually by 2035. Nearer term, the items that could move the story include a $5 million milestone payment tied to publication of the feline cancer study, potential licensing deals for the cancer and NETs technology, results from ongoing clinical studies at research centers in Europe and the United States, and continued validation and possible partnership announcements around Capture-Seq.
Note This
The licensing model is the thing to understand here. Volition is not trying to build labs and sales forces. It develops the science and the patents, then lets partners like Antech take products to market, which is how a small company already has a test selling on several continents.
What is still unproven is the human side. The veterinary product provides some commercial validation, but human cancer, sepsis and Capture-Seq remain largely in development, and the Capture-Seq numbers come from a single 81-subject cohort.
Volition is a development-stage company, and most of its potential value sits in products that have not yet reached routine clinical use.
| 1 | Cash burn and dilution. Development-stage diagnostics companies typically run at a loss for years, and Volition has relied on equity and debt financing to fund itself. Further raises would dilute existing shareholders. |
| 2 | The clinical data is still early. The Capture-Seq results come from a blinded cohort of 81 subjects, and small studies often look better than the larger ones that follow. The human Nu.Q applications still need broader validation. |
| 3 | Regulatory and reimbursement hurdles. A CE mark in Europe is not FDA clearance in the United States, the French reimbursement submission is still being prepared, and payer coverage decisions can take years. |
| 4 | Dependence on partners. Under a licensing model, revenue and milestone payments depend on partners like Antech choosing to commercialize the technology and succeeding at it, which Volition does not control. |
| 5 | Well-funded competition. Early cancer detection and liquid biopsy are dominated by much larger players with more capital, more data and existing sales channels, and timelines for a company of Volition's size can slip. |
The Bottom Line
Volition has a commercial product in veterinary cancer screening, a licensing model that has already produced $23 million in Antech payments, and a patent estate that runs to 2044. What it has not done yet is prove the human applications at scale. The veterinary business offers some commercial validation, while human cancer, sepsis and Capture-Seq remain largely in development, so the story turns on how the clinical data matures and whether the licensing discussions turn into deals.
Until Next Time,
-ZT Team
Please See Disclosures Below*
You are receiving this email because you subscribed to ZipTrader updates.
Tidak ada komentar:
Posting Komentar